Mir31 (microRNA 31) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Mir31 (microRNA 31) Rattus norvegicus
Symbol: Mir31
Name: microRNA 31
RGD ID: 2325391
Description: Predicted to enable mRNA 3'-UTR binding activity; mRNA CDS binding activity; and mRNA base-pairing translational repressor activity. Involved in several processes, including negative regulation of epithelial to mesenchymal transition; positive regulation of mesenchymal cell proliferation; and response to zinc ion. Predicted to be located in extracellular space and microvesicle. Predicted to be part of RISC complex. Used to study esophagus squamous cell carcinoma. Biomarker of hepatocellular carcinoma. Human ortholog(s) of this gene implicated in colorectal cancer and nasopharynx carcinoma. Orthologous to human MIR31 (microRNA 31); INTERACTS WITH 2-acetamidofluorene; 3,7-dihydropurine-6-thione; aflatoxin B1.
Type: ncrna
Previously known as: Mir31a; rno-mir-31; rno-mir-31a
RGD Orthologs
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.25103,599,038 - 103,599,143 (-)NCBImRatBN7.2mRatBN7.2
UTH_Rnor_SHR_Utx5106,031,567 - 106,031,672 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.05107,761,170 - 107,761,275 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.05107,834,100 - 107,834,205 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.05107,206,515 - 107,206,620 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_5.05111,183,081 - 111,183,186 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera5102,327,983 - 102,328,088 (-)NCBICelera
Cytogenetic Map5q32NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Gene Ontology Annotations     Click to see Annotation Detail View

Cellular Component

Molecular Function


References - curated
# Reference Title Reference Citation
1. Islet-1 is a dual regulator of fibrogenic epithelial-to-mesenchymal transition in epicardial mesothelial cells. Brønnum H, etal., Exp Cell Res. 2013 Feb 15;319(4):424-35. doi: 10.1016/j.yexcr.2012.12.019. Epub 2012 Dec 24.
2. MiR-31 Regulates Rho-Associated Kinase-Myosin Light Chain (ROCK-MLC) Pathway and Inhibits Gastric Cancer Invasion: Roles of RhoA. Chen Z, etal., Med Sci Monit. 2016 Dec 1;22:4679-4691. doi: 10.12659/msm.898399.
3. miR-31 is consistently inactivated in EBV-associated nasopharyngeal carcinoma and contributes to its tumorigenesis. Cheung CC, etal., Mol Cancer. 2014 Aug 7;13:184. doi: 10.1186/1476-4598-13-184.
4. LINC00689 participates in proliferation, chemoresistance and metastasis via miR-31-5p/YAP/β-catenin axis in colorectal cancer. Du YL, etal., Exp Cell Res. 2020 Oct 1;395(1):112176. doi: 10.1016/j.yexcr.2020.112176. Epub 2020 Jul 16.
5. MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. Edmonds MD, etal., J Clin Invest. 2016 Jan;126(1):349-64. doi: 10.1172/JCI82720. Epub 2015 Dec 14.
6. Abrogation of esophageal carcinoma development in miR-31 knockout rats. Fong LY, etal., Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):6075-6085. doi: 10.1073/pnas.1920333117. Epub 2020 Mar 2.
7. MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor α-1. Gwiggner M, etal., Genes (Basel). 2018 Feb 13;9(2). pii: genes9020085. doi: 10.3390/genes9020085.
8. Human miR-31 targets radixin and inhibits migration and invasion of glioma cells. Hua D, etal., Oncol Rep. 2012 Mar;27(3):700-6. doi: 10.3892/or.2011.1555. Epub 2011 Nov 15.
9. MicroRNA-31 reflects IL-6 expression in cancer tissue and is related with poor prognosis in bile duct cancer. Ishigami K, etal., Carcinogenesis. 2018 Sep 21;39(9):1127-1134. doi: 10.1093/carcin/bgy075.
10. MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Kim HS, etal., Oncotarget. 2015 Apr 10;6(10):8089-102.
11. Associations Between miRNAs and Two Different Cancers: Breast and Colon. Kundaktepe BP, etal., Cancer Manag Res. 2020 Feb 7;12:871-879. doi: 10.2147/CMAR.S227628. eCollection 2020.
12. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer. Laurent-Puig P, etal., Clin Cancer Res. 2019 Jan 1;25(1):134-141. doi: 10.1158/1078-0432.CCR-18-1324. Epub 2018 Aug 14.
13. MiR-31-5p acts as a tumor suppressor in renal cell carcinoma by targeting cyclin-dependent kinase 1 (CDK1). Li Y, etal., Biomed Pharmacother. 2019 Mar;111:517-526. doi: 10.1016/j.biopha.2018.12.102. Epub 2018 Dec 28.
14. Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. Liu CJ, etal., Oral Dis. 2010 May;16(4):360-4. doi: 10.1111/j.1601-0825.2009.01646.x. Epub 2010 Mar 9.
15. Conditional knockout of microRNA-31 promotes the development of colitis associated cancer. Liu Z, etal., Biochem Biophys Res Commun. 2017 Aug 12;490(1):62-68. doi: 10.1016/j.bbrc.2017.06.012. Epub 2017 Jun 6.
16. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Meng W, etal., Clin Cancer Res. 2013 Oct 1;19(19):5423-33. doi: 10.1158/1078-0432.CCR-13-0320. Epub 2013 Aug 14.
17. MiR-31-5p promotes the cell growth, migration and invasion of colorectal cancer cells by targeting NUMB. Peng H, etal., Biomed Pharmacother. 2019 Jan;109:208-216. doi: 10.1016/j.biopha.2018.10.048. Epub 2018 Nov 2.
18. LncRNA MIR31HG overexpression serves as poor prognostic biomarker and promotes cells proliferation in lung adenocarcinoma. Qin J, etal., Biomed Pharmacother. 2018 Mar;99:363-368. doi: 10.1016/j.biopha.2018.01.037.
19. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
20. Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection. Su Y, etal., Clin Epigenetics. 2016 Oct 19;8:109. doi: 10.1186/s13148-016-0275-5. eCollection 2016.
21. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). Sun D, etal., J Biol Chem. 2013 Mar 29;288(13):9508-18. doi: 10.1074/jbc.M112.367763. Epub 2013 Jan 15.
22. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Tan X, etal., Clin Cancer Res. 2011 Nov 1;17(21):6802-11. doi: 10.1158/1078-0432.CCR-11-0419. Epub 2011 Sep 2.
23. The potential role of microRNA-31 expression in early colorectal cancer. Tateishi Y, etal., Pathol Int. 2015 Oct;65(10):513-8. doi: 10.1111/pin.12334. Epub 2015 Jul 15.
24. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Wang CJ, etal., Dis Markers. 2009;26(1):27-34. doi: 10.3233/DMA-2009-0601.
25. MicroRNA-31/184 is involved in transforming growth factor-β-induced apoptosis in A549 human alveolar adenocarcinoma cells. Wang CJ, etal., Life Sci. 2020 Feb 1;242:117205. doi: 10.1016/j.lfs.2019.117205. Epub 2019 Dec 23.
26. Downregulated miR-31 level associates with poor prognosis of gastric cancer and its restoration suppresses tumor cell malignant phenotypes by inhibiting E2F2. Wang H, etal., Oncotarget. 2016 Jun 14;7(24):36577-36589. doi: 10.18632/oncotarget.9288.
27. MiR-31 Functions as a Tumor Suppressor in Lung Adenocarcinoma Mainly by Targeting HuR. Xu H, etal., Clin Lab. 2016;62(4):711-8.
28. Expression and significance of circulating microRNA-31 in lung cancer patients. Yan HJ, etal., Med Sci Monit. 2015 Mar 9;21:722-6. doi: 10.12659/MSM.893213.
29. Long non-coding RNA LOC554202 promotes laryngeal squamous cell carcinoma progression through regulating miR-31. Yang S, etal., J Cell Biochem. 2018 Aug;119(8):6953-6960. doi: 10.1002/jcb.26902. Epub 2018 May 8.
30. Circulating miR-31-5p may be a potential diagnostic biomarker in nasopharyngeal carcinoma. Yi SJ, etal., Neoplasma. 2019 Sep;66(5):825-829. doi: 10.4149/neo_2018_181109N847. Epub 2019 May 11.
31. CircRNA circ_0026344 as a prognostic biomarker suppresses colorectal cancer progression via microRNA-21 and microRNA-31. Yuan Y, etal., Biochem Biophys Res Commun. 2018 Sep 5;503(2):870-875. doi: 10.1016/j.bbrc.2018.06.089. Epub 2018 Jun 23.
32. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Zhang T, etal., Clin Sci (Lond). 2011 Nov;121(10):437-47. doi: 10.1042/CS20110207.
33. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Zhang Y, etal., Med Oncol. 2010 Sep;27(3):685-9. doi: 10.1007/s12032-009-9269-x. Epub 2009 Jul 14.
34. Increased expression of microRNA-31-5p inhibits cell proliferation, migration, and invasion via regulating Sp1 transcription factor in HepG2 hepatocellular carcinoma cell line. Zhao G, etal., Biochem Biophys Res Commun. 2017 Aug 19;490(2):371-377. doi: 10.1016/j.bbrc.2017.06.050. Epub 2017 Jun 13.
Additional References at PubMed
PMID:16381832   PMID:17604727   PMID:19147652   PMID:20403161   PMID:20548288   PMID:21993888   PMID:22020941   PMID:23517179   PMID:23646144   PMID:25168901   PMID:25728779   PMID:25751060  
PMID:28865712   PMID:29053138   PMID:29286111   PMID:29620173   PMID:32135167   PMID:33015806  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.25103,599,038 - 103,599,143 (-)NCBImRatBN7.2mRatBN7.2
UTH_Rnor_SHR_Utx5106,031,567 - 106,031,672 (-)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.05107,761,170 - 107,761,275 (-)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.05107,834,100 - 107,834,205 (-)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.05107,206,515 - 107,206,620 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_5.05111,183,081 - 111,183,186 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera5102,327,983 - 102,328,088 (-)NCBICelera
Cytogenetic Map5q32NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh38921,512,115 - 21,512,185 (-)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl921,512,115 - 21,512,185 (-)EnsemblGRCh38hg38GRCh38
GRCh37921,512,114 - 21,512,184 (-)NCBIGRCh37GRCh37hg19GRCh37
Build 36921,502,113 - 21,502,183 (-)NCBINCBI36Build 36hg18NCBI36
Celera921,450,429 - 21,450,499 (-)NCBICelera
Cytogenetic Map9p21.3NCBI
HuRef921,475,518 - 21,475,588 (-)NCBIHuRef
CHM1_1921,511,915 - 21,511,985 (-)NCBICHM1_1
T2T-CHM13v2.0921,526,301 - 21,526,371 (-)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39488,828,794 - 88,828,899 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl488,828,794 - 88,828,899 (-)EnsemblGRCm39 Ensembl
GRCm38488,910,557 - 88,910,662 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl488,910,557 - 88,910,662 (-)EnsemblGRCm38mm10GRCm38
MGSCv37488,556,461 - 88,556,566 (-)NCBIGRCm37MGSCv37mm9NCBIm37
Celera487,392,515 - 87,392,620 (-)NCBICelera
Cytogenetic Map4C4NCBI
cM Map442.05NCBI
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.11140,904,438 - 40,904,496 (-)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1140,904,437 - 40,904,503 (-)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1139,576,885 - 39,576,943 (-)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01141,846,612 - 41,846,670 (-)NCBIROS_Cfam_1.0
UMICH_Zoey_3.11140,518,076 - 40,518,134 (-)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01140,405,265 - 40,405,323 (-)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01141,018,979 - 41,019,037 (-)NCBIUU_Cfam_GSD_1.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl1201,198,732 - 201,198,809 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11201,198,732 - 201,198,809 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21224,397,161 - 224,397,238 (+)NCBISscrofa10.2Sscrofa10.2susScr3

miRNA Target Status

Confirmed Targets
Gene TargetMature miRNAMethod NameResult TypeData TypeSupport TypePMID
Isl1rno-miR-31a-5pMirtarbaseexternal_infoImmunofluorescence//Luciferase reporter assayFunctional MTI23270756
Klf5rno-miR-31a-5pMirtarbaseexternal_infoReporter assayFunctional MTI19542014

Predicted Targets
Summary Value
Count of predictions:8927
Count of gene targets:5579
Count of transcripts:5975
Interacting mature miRNAs:rno-miR-31a-3p, rno-miR-31a-5p
Prediction methods:Microtar, Miranda, Pita, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
70212Niddm25Non-insulin dependent diabetes mellitus QTL 253.54blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)51131345958Rat
1576314Eutr1Estrogen induced uterine response QTL 1uterus integrity trait (VT:0010575)pyometritis severity score (CMO:0002009)52138965166875058Rat
634305Mamtr1Mammary tumor resistance QTL 10.0001mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)512789751113558310Rat
2290448Scl54Serum cholesterol level QTL 542.93blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)531663789131345958Rat
1576317Eutr2Estrogen induced uterine response QTL 20.01uterus integrity trait (VT:0010575)pyometritis severity score (CMO:0002009)534730116104251008Rat
2316959Gluco59Glucose level QTL 594.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)534944474113558310Rat
1641912Alcrsp18Alcohol response QTL 18response to alcohol trait (VT:0010489)duration of loss of righting reflex (CMO:0002289)535189153141643988Rat
1549845Scl44Serum cholesterol level QTL 446blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)540128307148607290Rat
1331801Rf33Renal function QTL 334.149kidney blood vessel physiology trait (VT:0100012)absolute change in renal vascular resistance (CMO:0001900)543726656129132602Rat
1578766Tcas11Tongue tumor susceptibility QTL 114.12tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)546711509161317411Rat
1576312Emca8Estrogen-induced mammary cancer QTL 84.1mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)550328551141643988Rat
70189Mcs5Mammary carcinoma susceptibility QTL 510.51mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)555805606132207589Rat
1358895Bp254Blood pressure QTL 2543.60.0003arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)558829236128034027Rat
61426Scl2Serum cholesterol level QTL 27.30.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)559793399143070159Rat
2316957Pur21Proteinuria QTL 216.2urine protein amount (VT:0005160)urine protein level (CMO:0000591)559793528113558156Rat
61393Bp7Blood pressure QTL 74.50.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)560293434161481680Rat
2290005Mcs24Mammary carcinoma susceptibility QTL 24mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)564719390109719390Rat
2306971Anxrr21Anxiety related response QTL 219.47fear/anxiety-related behavior trait (VT:1000241)number of entries into a discrete space in an experimental apparatus (CMO:0000960)566174080124160948Rat
2312671Scl64Serum cholesterol level QTL 640.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)568984307104251008Rat
61380Edpm5Estrogen-dependent pituitary mass QTL 54.50.92pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)568984307104251008Rat
1357396Bw44Body weight QTL 444.19body mass (VT:0001259)body weight (CMO:0000012)568984307104251008Rat
1357402Bw46Body weight QTL 464.47body mass (VT:0001259)body mass index (BMI) (CMO:0000105)568984307104251008Rat
2302381Bw84Body weight QTL 844.47body mass (VT:0001259)body mass index (BMI) (CMO:0000105)568984307104251008Rat
1354598Srn6Serum renin concentration QTL 63.8blood renin amount (VT:0003349)plasma renin activity level (CMO:0000116)569540295151018848Rat
1298070Scl18Serum cholesterol level QTL 183.7blood LDL cholesterol amount (VT:0000181)calculated plasma low density lipoprotein cholesterol level (CMO:0001245)579584860124584860Rat
1598846Bp293Blood pressure QTL 2933.9arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)579584860124584860Rat
1598859Cm66Cardiac mass QTL 662heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)579584860124584860Rat
1302790Scl20Serum cholesterol level QTL 206.40.0001blood cholesterol amount (VT:0000180)plasma total cholesterol level (CMO:0000585)582394392166664054Rat
1298086Bp156Blood pressure QTL 156arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)584132602129132602Rat
7411601Foco12Food consumption QTL 1219.70.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)587468046132468046Rat
7411564Bw135Body weight QTL 1350.001body mass (VT:0001259)body weight gain (CMO:0000420)587468046132468046Rat
7411582Foco3Food consumption QTL 37.50.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)587468046132468046Rat
6903316Bw113Body weight QTL 11320.0103body mass (VT:0001259)body weight (CMO:0000012)587765973132765973Rat
1358889Bp261Blood pressure QTL 2612.86arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)590067849128034027Rat
1358909Kidm25Kidney mass QTL 251.87kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)590067849128034027Rat
631527Tls1T-lymphoma susceptibility QTL 100.001thymus integrity trait (VT:0010555)post-insult time to onset of T-cell lymphoma (CMO:0001907)590450144135450144Rat
61452Ciaa5CIA Autoantibody QTL 53.5blood autoantibody amount (VT:0003725)calculated serum anti-rat type 2 collagen autoantibody titer (CMO:0001281)594858972143070159Rat
1331796Thshl2Thyroid stimulating hormone level QTL 22.3blood thyroid-stimulating hormone amount (VT:0005119)serum thyroid stimulating hormone level (CMO:0001248)597059760147465714Rat
2317753Glom24Glomerulus QTL 243.1kidney glomerulus integrity trait (VT:0010546)kidney sclerotic glomeruli count to total glomeruli count ratio (CMO:0001269)597570330136479578Rat
1582212Livw2Liver weight QTL 23.50.0004liver mass (VT:0003402)liver weight to body weight ratio (CMO:0000633)599016066119085810Rat
1358187Emca1Estrogen-induced mammary cancer QTL 14.4mammary gland integrity trait (VT:0010552)post-insult time to mammary tumor formation (CMO:0000345)599216724148607142Rat
1600362Mcs19Mammary carcinoma susceptibility QTL 192.5mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)599485997103690167Rat
7394708Emca11Estrogen-induced mammary cancer QTL 11mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)599753548113061097Rat



Nucleotide Sequences
RefSeq Transcripts NR_031845 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles
GenBank Nucleotide JACYVU010000162 (Get FASTA)   NCBI Sequence Viewer   Search GEO for Microarray Profiles

RefSeq Acc Id: NR_031845
Rat AssemblyChrPosition (strand)Source
mRatBN7.25103,599,038 - 103,599,143 (-)NCBI
Rnor_6.05107,206,515 - 107,206,620 (+)NCBI
Rnor_5.05111,183,081 - 111,183,186 (+)NCBI
Celera5102,327,983 - 102,328,088 (-)NCBI

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2325391 AgrOrtholog
BioCyc Gene G2FUF-40790 BioCyc
miRBase MI0000872 ENTREZGENE
NCBI Gene 100314232 ENTREZGENE
PhenoGen Mir31 PhenoGen
RNAcentral URS00000DE5AF RNACentral
  URS00002B9AD0 RNACentral
  URS000075D93C RNACentral

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2015-04-09 Mir31  microRNA 31  Mir31  microRNA mir-31  Name updated 61478 APPROVED
2010-06-02 Mir31  microRNA mir-31      Symbol and Name status set to provisional 70820 PROVISIONAL